FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Exelixis's Free Cash Flow for the
three
months ended in Dec. 2023 was $-3 Mil. Exelixis's Revenue for the
three
months ended in Dec. 2023 was $480 Mil. Therefore, Exelixis's FCF Margin % for the quarter that ended in Dec. 2023 was -0.53%.
The historical rank and industry rank for Exelixis's FCF Margin % or its related term are showing as below:
EXEL'
s FCF Margin % Range Over the Past 10 Years
Min: -939.35 Med: 20.78 Max: 109.01
Current: 9.31
During the past 13 years, the highest FCF Margin % of Exelixis was 109.01%. The lowest was -939.35%. And the median was 20.78%.
EXEL's FCF Margin % is ranked better than 85.95% of 1032
companies
in the Biotechnology industry
Industry Median: -148.935
vs EXEL: 9.31
Exelixis FCF Margin % Historical Data
The historical data trend for Exelixis's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Exelixis's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exelixis's FCF Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Exelixis's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Exelixis's FCF Margin % falls into.
Exelixis FCF Margin % Calculation
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
Exelixis's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exelixis FCF Margin % Related Terms
Thank you for viewing the detailed overview of Exelixis's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EXEL has been successfully added to your 